Seven Fleet Capital Management LP Has $5.93 Million Position in Xencor, Inc. $XNCR

Seven Fleet Capital Management LP lifted its position in Xencor, Inc. (NASDAQ:XNCR) by 360.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 368,305 shares of the biopharmaceutical company’s stock after buying an additional 288,305 shares during the period. Xencor makes up about 1.0% of Seven Fleet Capital Management LP’s portfolio, making the stock its 22nd largest position. Seven Fleet Capital Management LP’s holdings in Xencor were worth $5,930,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP bought a new position in shares of Xencor during the 2nd quarter valued at about $55,000. Tower Research Capital LLC TRC grew its position in shares of Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. bought a new stake in Xencor during the 2nd quarter worth approximately $79,000. Norges Bank acquired a new stake in Xencor during the 4th quarter worth approximately $175,000. Finally, Prelude Capital Management LLC bought a new position in Xencor in the third quarter valued at approximately $139,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Royal Bank Of Canada increased their price objective on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Truist Financial dropped their price target on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. upped their price objective on Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.71.

Xencor Stock Down 0.0%

NASDAQ:XNCR opened at $26.61 on Friday. Xencor, Inc. has a twelve month low of $8.19 and a twelve month high of $30.61. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -12.26 and a beta of 0.88. The stock’s 50 day moving average price is $21.06 and its two-hundred day moving average price is $15.30.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the prior year, the firm posted ($0.41) EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. As a group, analysts anticipate that Xencor, Inc. will post -3 earnings per share for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.